Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843262 | 0.92 | RAB9A (0.43) | RAB9ALMNAGAAMAPTFKBP1A | |
| SCHEMBL4838603 | 0.91 | RAB9A (0.44) | RAB9ALMNAL3MBTL1GAAMAPT | |
| SCHEMBL4838548 | 0.89 | ALDH1A1 (0.46) | RAB9ALMNATP53MAPT | |
| SCHEMBL4837654 | 0.89 | TRPA1 (0.44) | MAPTMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4844332 | 0.87 | MEN1 (0.40) | LMNAMAPTFKBP1AMEN1CYP3A4 | |
| SCHEMBL4832807 | 0.87 | MAPT (0.44) | RAB9ALMNAGAAMAPTFKBP1A | |
| SCHEMBL4841036 | 0.84 | ALDH1A1 (0.42) | LMNAMAPTMEN1CYP3A4CYP2D6 | |
| SCHEMBL4833457 | 0.84 | MMP8 (0.40) | LMNAMAPTFKBP1AMEN1CYP3A4 | |
| SCHEMBL4842829 | 0.83 | SCN9A (0.48) | LMNAMAPTFKBP1AMEN1CYP3A4 | |
| SCHEMBL4841170 | 0.82 | TRPA1 (0.44) | LMNAMAPTMEN1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | RAB9A 2028/4885LMNA 1943/4885L3MBTL1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.